The disclosure is directed to a device for electroporating and delivering one or more antigens and a method of electroporating and delivering one or more antigens to cells of epidermal tissues using the device. The device comprises a housing, a plurality of electrode arrays projecting from the housing, each electrode array including at least one electrode, a pulse generator electrically coupled to the electrodes, a programmable microcontroller electrically coupled to the pulse generator, and an electrical power source coupled to the pulse generator and the microcontroller. The electrode arrays define spatially separate sites.

Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.

The disclosure is directed to a device for electroporating and delivering one or more antigens and a method of electroporating and delivering one or more antigens to cells of epidermal tissues using the device. The device comprises a housing, a plurality of electrode arrays projecting from the housing, each electrode array including at least one electrode, a pulse generator electrically coupled to the electrodes, a programmable microcontroller electrically coupled to the pulse generator, and an electrical power source coupled to the pulse generator and the microcontroller. The electrode arrays define spatially separate sites.

A plasma torch having an open end from which a plasma plume is emitted in use is disclosed. The plasma torch includes a central cathode rod, a grounded conductive tube having an open end and being arranged around the cathode and spaced therefrom to form a first cylindrical cavity open at one end; and a high voltage electrode having a dielectric barrier material at a radially inward-facing surface thereof and being arranged around the grounded conductive tube and spaced apart therefrom to form a second annular cylindrical cavity open at one end. A constant direct current (DC) electrical power plus a high voltage pulsed electrical power is provided to the cathode producing an arc discharge in the first cavity between the cathode and grounded tube to generate a central thermal plasma emitted at an open end of the first cylindrical cavity. A high voltage alternating current electrical power or pulsed electrical power is provided to the high voltage electrode producing a dielectric barrier discharge in the second annular cylindrical cavity to generate a non-thermal plasma emitted from an open end of the second cavity as a halo around the central thermal plasma.

An electroporation device with a needle array removably attached thereto, the needle array having a body, a shroud movable with respect to the body between a rest position and one or more actuated positions, and an auto-lock assembly. Where the auto-lock assembly is adjustable between a locked configuration, where the shroud is not movable with respect to the body, and an unlocked configuration, where the shroud is movable with respect to the body, and where biasing the shroud from the rest position to the one or more actuated positions and back to the rest position adjusts the auto-lock from the unlocked configuration to the locked configuration.

Techniques for treating subjects with an injected agent include applying vacuum pressure to tissue adjacent the injection and optionally electroporating said tissue. A device for applying such treatment includes a housing defining a receptacle and an opening into the receptacle. A port extends through the housing remote from the opening and is connectable to a vacuum source, such that the port can communicate vacuum pressure from the vacuum source to the receptacle. The device includes an insert that is receivable within the receptacle and that defines an internal chamber, which is in communication with the vacuum source when the insert resides in the receptacle. The insert includes at least one electrode positioned within the chamber and configured to deliver one or more electroporation pulses to a targeted portion of tissue extending through the at least one opening and at least momentarily held in the chamber responsive to the vacuum pressure.

Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.

Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.

The present invention relates to electroporation (EP) devices that are able to generate an electroporation causing electrical field at the mucosal layer, and preferably in a tolerable manner. Further, it includes the generation of a protective immune response, cellular and/or humoral, using the oral EP device along with a genetic construct that encodes an immunogenic sequence.

A transdermal dihydrogen delivery device including a body including an anode and a cathode, and an electrical energy source, wherein the body is based on a flexible material, capable of shaping to the skin of a human or animal body, and the body includes a water receptacle, the relative arrangement of the receptacle, the anode and the cathode being configured such that the water contained in the receptacle is in contact with the anode and the cathode to form a closed electrical circuit, so as to produce dihydrogen at the cathode from the water taken from the receptacle, to release transdermally the dihydrogen produced. The proposed delivery device is relatively non-invasive, while allowing dihydrogen delivery.